Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine
Status:
Unknown status
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
Human immunodeficiency virus infection and highly active antiretroviral therapy (HAART) are
associated with an increased risk of cardiovascular disease: a wide range of alterations in
lipid and glucose metabolism has been increasingly recognized in HIV patients treated with
HAART. Few data are available on the effects of antihypertensive treatment on cardiac
morpho-functional characteristics and metabolic parameters in HIV patients. Aim of the study
is to assess the effects of chronic therapy with angiotensin receptor blocker(candesartan)or
calcium channel blocker (lercanidipine)on metabolic profile and cardiac remodelling in HIV
hypertensive patients.